Javascript must be enabled to continue!
Pharmacokinetic modelling of valproate in epileptic patients
View through CrossRef
Introduction. The aim of our study was to develop and use a population
pharmacokinetic model for assessment of individual valproate clearance in
children and young adults suffering from epilepsy. Material and methods. The
analysis was performed using 52 steady-state concentrations of valproate
collected from 26 epileptic patients during the routine clinical practice in
our hospital. The mean values of age and total body weight were 19.92 years
and 57.12 kg, respectively. NONMEM software with ADVAN 1 subroutine was used
for model building and assessing the influence of different covariates. A
validation set of 20 epileptic patients (one blood sample per a patient) was
used to estimate predicted performances of the pharmacokinetic model.
Results. The typical mean value of the clearance of valproate estimated by
the base model in our population was 0.377 l/h. Out of five considered
covariates (total body weight, age, total daily dose, gender and polytherapy)
only the age of the patients was a significant determinant of the clearance
of valproate. The final regression model for the clearance of valproate was
as following: CL (l/h) = 0.223 + 0.00819
National Library of Serbia
Title: Pharmacokinetic modelling of valproate in epileptic patients
Description:
Introduction.
The aim of our study was to develop and use a population
pharmacokinetic model for assessment of individual valproate clearance in
children and young adults suffering from epilepsy.
Material and methods.
The
analysis was performed using 52 steady-state concentrations of valproate
collected from 26 epileptic patients during the routine clinical practice in
our hospital.
The mean values of age and total body weight were 19.
92 years
and 57.
12 kg, respectively.
NONMEM software with ADVAN 1 subroutine was used
for model building and assessing the influence of different covariates.
A
validation set of 20 epileptic patients (one blood sample per a patient) was
used to estimate predicted performances of the pharmacokinetic model.
Results.
The typical mean value of the clearance of valproate estimated by
the base model in our population was 0.
377 l/h.
Out of five considered
covariates (total body weight, age, total daily dose, gender and polytherapy)
only the age of the patients was a significant determinant of the clearance
of valproate.
The final regression model for the clearance of valproate was
as following: CL (l/h) = 0.
223 + 0.
00819.
Related Results
Valproate Annual Risk Acknowledgement Form: Evaluating Compliance and Creating Digital Solutions
Valproate Annual Risk Acknowledgement Form: Evaluating Compliance and Creating Digital Solutions
Aims: Valproate is a commonly prescribed drug in neurology and psychiatry, licensed for epilepsy as an anticonvulsant and in bipolar disorder as a mood stabiliser. Valproate is hig...
A comparative study to investigate the level of cognitive impairment among epileptic and psychogenic non-epileptic patients
A comparative study to investigate the level of cognitive impairment among epileptic and psychogenic non-epileptic patients
Abstract
Objective: To compare cognitive impairment between patients having epileptic seizures and those having psychogenic non-epileptic seizures.
Methods: The cross-s...
The Impact of Sodium Valproate on Male Reproductive Health: A Comprehensive Review
The Impact of Sodium Valproate on Male Reproductive Health: A Comprehensive Review
Sodium Valproate is one of the most prescribed antiepileptic drugs and it leads to severe reproductive problems among men. The objective of this review is to provide an overview ab...
Teratogenic effects on the neuroepithelium of the CD‐1 mouse embryo exposed in utero to sodium valproate
Teratogenic effects on the neuroepithelium of the CD‐1 mouse embryo exposed in utero to sodium valproate
AbstractA causal association has now been recognized between the use of the anticonvulsant drug sodium valproate during pregnancy and the increased incidence of spina bifida in the...
KEPPRA (Levetiracetum) VS EPIVAL (Sodium Valporate) to control generalized tonic clonic seizures.
KEPPRA (Levetiracetum) VS EPIVAL (Sodium Valporate) to control generalized tonic clonic seizures.
Objective: This present study is design to assess the efficacy and frequency of side effects with a newer anti-epileptic agent levertiracetum while comparing an older anti-epilepti...
COMPARATIVE EFFICACY OF LEVETIRACETAM AND SODIUM VALPROATE IN THE TREATMENT OF EARLY CHILDHOOD EPILEPSY
COMPARATIVE EFFICACY OF LEVETIRACETAM AND SODIUM VALPROATE IN THE TREATMENT OF EARLY CHILDHOOD EPILEPSY
Background: Epilepsy is among the most common chronic neurological disorders in children, with considerable impact on cognitive and psychosocial development. Sodium valproate is a ...
A Contribution to the Genetics of Febrile Seizures: Waking and Sleep EEG in Siblings
A Contribution to the Genetics of Febrile Seizures: Waking and Sleep EEG in Siblings
Summary: Waking and sleep EEGs were recorded in 67 siblings of 52 patients with febrile seizures (FS). Epileptic activity was noted in at least 1 sibling for 28 of the 52 patients...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
10th Annual Meeting, 25‐26 November 1976, Adelaide 1. Histamine metabolism in aortae of two histamine sensitive species. A. Foldes, M. J. Stacey and I. S. de la Lande 2. Localizat...

